<DOC>
	<DOCNO>NCT01362426</DOCNO>
	<brief_summary>The primary objective study determine Australian patient schizophrenia treat paliperidone palmitate condition continuous monitor outcomes 12-month period achieve relapse rate comparable publish literature .</brief_summary>
	<brief_title>Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal ( PEARL )</brief_title>
	<detailed_description>This study involve establishment PEARL , Australian Quality Use Medicine clinical registry design collect clinical social data 300 patient schizophrenia 12-month period initiate treatment intramuscular ( IM ) injection paliperidone palmitate part routine clinical care . Continuous feedback clinical outcome via regular report registry site . Enrollment PEARL consider clinical decision prescribe IM paliperidone palmitate already make treat physician determine treatment best option patient . Observational Study - No investigational drug administer</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Must fulfill diagnostic criterion Schizophrenia Disorders define Diagnostic Statistical Manual Mental Disorders Version IV ( DSMIV ) Must meet approve Therapeutic Goods Administration ( TGA ) indication injectable paliperidone palmitate Must provide write informed consent indicate understand purpose procedure require registry willing participate registry . Those know hypersensitivity either paliperidone risperidone , excipients paliperidone palmitate formulation Employees clinician study centre , direct involvement propose registry study direction clinician study centre , well family member employee clinician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>paliperidone palmitate</keyword>
	<keyword>INVEGA SUSTENNA</keyword>
	<keyword>registry</keyword>
	<keyword>quality healthcare</keyword>
</DOC>